Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Provides Insights on Definitive Agreement to Combine with GEDi Cube to Transform Medicine

  • Combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early cancer detection, diagnostic insights, and targeted immunotherapies
  • The decision to join forces resulted from a carefully considered strategy to combine strengths and synergize work to elevate therapeutic efficacy and patient care
  • By joining forces, the two technology divisions will collaborate to push new boundaries in precision diagnostics and targeted treatments
  • GEDi Cube’s AI algorithms, trained using real-world data, could guide and accelerate Renovaro’s therapy development
  • Renovaro’s intimate knowledge about vital aspects of the immune system and how cancers could respond to treatment may help strengthen GEDi Cube’s AI technology

Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell, and immunotherapy platforms that modulate immune responses against cancers and infectious diseases, and GEDi Cube International Ltd., an AI medical technology company, recently signed a definitive agreement to combine in a stock-for-stock acquisition (

The combined company brings together renowned leaders across AI and immunotherapy, including Dr. Dybul, who brings decades of global health leadership experience; GEDi Cube CEO Craig Rhodes, the former head of Life Sciences for Europe, the Middle East, and North Africa at NVIDIA; Gregg Alton, former interim CEO of Gilead Sciences; and Dr. Anahid Jewett, Professor and Director of the tumor immunology laboratory at UCLA; just to mention a few.

Once completed, the transaction will result in a combined company in which GEDi Cube will become a wholly-owned subsidiary of Renovaro, rebranding as Renovaro.AI.  GEDi Cube CEO Craig Rhodes will lead

The combined company will feature two main divisions: the AI division and the immunotherapy division, according to an October 2 message to shareholders from Renovaro CEO Mark Dybul, M.D. With a mission to transform medicine, the two divisions will leverage the strengths of each other yet maintain flexible independent operations. Bringing together two innovative platforms in biotherapeutics and AI, the combined company intends to create comprehensive solutions for early cancer detection, diagnostic insights, and effective targeted immunotherapies. It is the intent of both organizations that Mark Dybul will lead.

“We believe the combination will accelerate our shared mission to transform medicine and promote healthy longevity through the synergistic applications of advanced AI technology and pioneering biotherapeutics,” wrote Dr. Dybul. In the message, Dr. Dybul provided insights on the news of the definitive agreement and shared the vision for the newly combined company (

According to Dr. Dybul, GEDi Cube and Renovaro Biosciences came together through a shared desire to turbo-charge innovation and efficacy in precision medicine. The decision to join forces resulted from a carefully considered strategy to combine strengths and synergize work to improve patient outcomes by detecting diseases sooner and matching treatments more precisely based on the individual’s genetic profile.

On its part, GEDi Cube has developed and honed its proprietary AI technology over the past decade. The technology uses differential multi-omics analysis to pinpoint molecular patterns that detect cancer sooner than standard techniques. The analysis searches for patterns across transcriptomics, epigenomics, genomics, among others to identify informative biomarkers. So far, the technology can identify biomarkers for over 12 cancers. GEDi Cube’s AI technology has shown 95% accuracy in detecting cancers earlier by analyzing complex molecular data.

Recently, GEDi Cube joined NVIDIA (NASDAQ: NVDA) Inception, a program that nurtures budding companies by providing access to cutting-edge technology, technical resources, and venture capitalists. As a result of this strategic partnership, GEDi Cube will supplement its proprietary technology with NVIDIA’s advanced medical imaging capabilities to create an algorithm that relies on both the omic and imaging modals ( According to Dr. Dybul, this is poised to help GEDi Cube improve diagnostic accuracy further.

Renovaro Biosciences, on its part, has developed an advanced immunotherapy platform focused initially on lethal solid tumor cancers that have seen limited improvements in survival rates. The company uses a patented approach that modifies allogeneic dendritic cells to stimulate anti-tumor immunity specific to a patient’s genetic profile. In pancreatic cancer models, this technology has shown an 80-90% reduction in tumor size.

“As we learned about each technology, it rapidly became apparent that combining Renovaro’s immunotherapies with GEDi Cube’s AI-driven early diagnostic capabilities, its potential to help determine cancers to target for therapy, to monitor the effectiveness of therapy, and even discovering new approaches to treatment could lead to a powerful synergy,” explained Dr. Dybul.

Moreover, GEDi Cube’s AI algorithms, trained using real-world data, could guide and accelerate Renovaro’s therapy development, while Renovaro’s data repository, which includes, among others, knowledge about critical aspects of the immune system that relate to how cancers could respond to treatment, could help strengthen GEDi Cube’s AI technology.

Dr. Dybul expressed his optimism about the growth trajectory ahead, highlighting that the combined company intends to launch multiple revenue-generating products beginning in 2024. The AI division plans to launch commercial products for early cancer detection and improved therapy selection in 2024.

The immunotherapy division intends to start Phase 1/2 trials of Renovaro’s lead asset in the second half of 2024. The commencement of the trials is expected to possibly lead to emergency use authorization as soon as the end of 2027 following the results of a Phase 2 clinical trial. Dr. Dybul anticipates that the potential emergency use authorization will transform treatment for cancers with stagnant survival rates like pancreatic cancer.

“United, we believe we can achieve the shared goal of delivering more effective, proactive, and personalized care to the patients who need it,” concluded Dr. Dybul.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

This entry was posted in Renovaro BioSciences Inc. RENB. Bookmark the permalink.

Comments are closed.